Pajk B, Cufer T, Cervek J, Zakotnik B
Institute of Oncology, Ljubljana, Slovenia.
Tumori. 1996 Sep-Oct;82(5):453-5. doi: 10.1177/030089169608200508.
To determine the effectiveness of combination chemotherapy with cisplatin, methotrexate and vinblastine (CMV), we treated 21 chemotherapy naive patients with metastatic transitional cell carcinoma of the bladder. Chemotherapy consisted of methotrexate (30 mg/m2 i.v. days 1 and 8), vinblastine (3 mg/m2 i.v. days 1 and 8) and cisplatin (100 mg/m2 i.v. day 2) every three weeks. Dominant metastatic sites were: soft tissues (7 patients), bone (6 patients), lung and liver (8 patients). A complete remission was achieved in 5/21 patients (24%, 95% CI 8-47%) and partial remission in 9/21 patients (43%, 95% CI 22-66%). The median duration was 6 months (2-11) and 9 months (2-26) for complete and partial remissions, respectively. The median survival for all 21 patients was 10 months. Although overall toxicity was mild, we observed myelosuppression grade IV in 2 patients, stomatitis grade III in 2 patients, cystitis grade III in 1 patient and infection grade III in 6 patients. There were no treatment-related deaths. Our data indicate that treatment with the CMV regimen is effective and that side effects are tolerable.
为确定顺铂、甲氨蝶呤和长春碱联合化疗（CMV）的疗效，我们对21例初治的膀胱转移性移行细胞癌患者进行了治疗。化疗方案为每三周一次，具体药物包括甲氨蝶呤（30mg/m²静脉注射，第1天和第8天）、长春碱（3mg/m²静脉注射，第1天和第8天）和顺铂（100mg/m²静脉注射，第2天）。主要转移部位为：软组织（7例患者）、骨（6例患者）、肺和肝（8例患者）。21例患者中有5例（24%，95%置信区间8%-47%）达到完全缓解，9例（43%，95%置信区间22%-66%）达到部分缓解。完全缓解和部分缓解的中位持续时间分别为6个月（2-11个月）和9个月（2-26个月）。21例患者的中位生存期为10个月。虽然总体毒性较轻，但我们观察到2例患者出现IV级骨髓抑制，2例患者出现III级口腔炎，1例患者出现III级膀胱炎，6例患者出现III级感染。无治疗相关死亡。我们的数据表明，CMV方案治疗有效且副作用可耐受。
